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OBJECTIVES: Prevention of the development of paraplegia during the repair of the damage caused by
descending thoracic and thoracoabdominal aneurysms remains an important issue. Therefore, we investigated
the protective effect of atorvastatin on ischemia-induced spinal cord injury in a rabbit model.
METHOD: Thirty-two rabbits were divided into the following four equally sized groups: group I (control), group
II (ischemia-reperfusion), group III (atorvastatin treatment) and group IV (atorvastatin withdrawal). Spinal cord
ischemia was induced by clamping the aorta both below the left renal artery and above the iliac bifurcation.
Seventy-two hours postoperatively, the motor function of the lower limbs of each animal was evaluated
according to the Tarlov score. Spinal cord and blood samples were obtained for histopathological and
biochemical analyses.
RESULTS: All of the rabbits in group II exhibited severe neurological deficits. Atorvastatin treatment (groups III
and IV) significantly reduced the level of motor dysfunction. No significant differences were observed between
the motor function scores of groups III and IV at the evaluated time points. Light microscopic examination of
spinal cord tissue samples obtained at the 72nd hour of reperfusion indicated greater tissue preservation in
groups III and IV than in group II.
CONCLUSION: This study demonstrates the considerable neuroprotective effect of atorvastatin on the
neurological, biochemical and histopathological status of rabbits with ischemia-induced spinal cord injury.
Moreover, the acute withdrawal of atorvastatin therapy following the induction of spinal cord ischemia did not
increase the neuronal damage in this rabbit model.
KEYWORDS: Atorvastatin; Spinal Cord; Ischemia-Reperfusion Injury.
Nazli Y, Colak N, Alpay MF, Uysal S, Uzunlar AK, Cakir O. Neuroprotective effect of atorvastatin in spinal cord ischemia-reperfusion
injury. Clinics. 2015;70(1):52-60.
Received for publication on April 25, 2014; First review completed on July 6, 2014; Accepted for publication on July 18, 2014
E-mail: yunusnazli@gmail.com
*corresponding author
& INTRODUCTION
Spinal cord injury remains a devastating complication of
thoracic and thoracoabdominal aortic interventions, with a
reported incidence ranging from 2.4% to 40% (1). To avoid
this complication, various methods to protect the spinal cord
have been suggested, including the placement of temporary
shunts or performing a partial cardiopulmonary bypass,
draining the cerebrospinal fluid, inducing hypothermia and
administering pharmacologics. Regardless of the surgical
technique or procedure used to protect the spinal cord,
these methods do not entirely prevent the development of
paraplegia. Current pharmacological studies on more effica-
cious methods include the use of steroids, oxygen-derived
free radical scavengers, vasodilators and drugs designed to
achieve electrical silence in the spinal cord during the
ischemia-reperfusion period (2,3,4).
The 3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors (also known as statins) are the most widely used
cholesterol-lowering medications. Previous clinical investi-
gations have demonstrated that statins cause a significant
decrease in the incidence of ischemic stroke in patients with
and without high levels of serum cholesterol (5). Thus, it has
been suggested that statins may exhibit neuroprotective
properties that contribute to a reduction in the severity of the
pathophysiological processes induced by the ischemic insult
via a mechanism that is independent of their cholesterol-
lowering effect (6). Animal studies have demonstrated that
statins may be protective in ischemic stroke, most likely
because of their effects on different isoforms of nitric oxide
synthase (NOS), which can lead to the restoration of cerebral
blood flow (7,8). Moreover, statins can decrease the extent of
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vascular inflammatory responses, modulate cytokine pro-
duction and promote angiogenesis. Nevertheless, the neuro-
protective effect of statins in ischemic stroke remains
controversial (8,9,10).
In this study, we examined the neurological, histopatho-
logical and biochemical effects of atorvastatin in experi-
mental ischemic spinal-cord injury.
& MATERIALS AND METHODS
The experimental protocol was approved by the Fatih
University Institutional Animal Care and Use Committee.
All of the experimental animals received humane care and
treatment in accordance with the ‘‘Guide for the Care and
Use of Laboratory Animals’’ developed by the Institute of
Laboratory Animal Resources, National Research Council
and published by the National Academy Press, revised
1996.
Experimental protocol
Thirty-two New Zealand white rabbits weighing between
2.4 and 3.5 kg were initially anesthetized using intramus-
cular ketamine hydrochloride (50 mg/kg) and xylazine
(5 mg/kg) and were administered a half-dose as required
during the procedure. The animals were allowed to breathe
room air without mechanical ventilation. The body tem-
perature was maintained at approximately 38 C˚ using a
heating lamp. An ear vein and artery were cannulated prior
to surgery. The arterial pressure and heart rate were
continuously monitored. Preoperative cefazolin (10 mg/
kg) was administered in a single dose. After the animal’s
abdomen was cleaned using an antiseptic solution, the
abdomen was entered through a median laparotomy and
the abdominal aorta was exposed inferiorly to the left renal
artery and down to the level of the bifurcation. The aorta
was encircled with a silk ligature distal to the renal artery
and proximal to the bifurcation to facilitate performing a
secure occlusion. Each rabbit was administered heparin for
anticoagulation at 150 IU/kg prior to aortic cross-clamping.
The aorta was occluded for 20 min distal to the renal artery
using a pediatric vascular clamp and proximal to the
bifurcation using a similar clamp. Following release of the
aortic occlusion, the abdomen was closed in layers and
the animals were allowed to recover. The procedure was
performed in an identical fashion on animals in the control
group but without aortic occlusion. The hemodynamic
variables (blood pressure and heart rate) and body
temperature were continuously monitored throughout the
experiment. The arterial blood gas values were determined
five minutes prior to the induction of ischemia, during
ischemia and ischemia. No differences were found among
the experimental groups with respect to the mean arterial
blood pressure, heart rate, arterial blood gas values or body
temperature.
In the atorvastatin groups (groups III and IV), 2.5 mg/
kg/day atorvastatin (Lipitor, Parke-Davis, Division of Pfizer
Inc., New York, USA) was orally administered; in the I/R
group, a similar amount of sterile saline solution was orally
administered. In group III, atorvastatin administration
began 14 days prior to aortic cross-clamping and was
continued for the first two days of the reperfusion period. In
group IV (the withdrawal group), atorvastatin was admi-
nistered 14 days prior to aortic cross-clamping but was not
administered during the reperfusion period.
All of the animals were euthanized at 72 h postopera-
tively using a lethal cardiac injection of pentobarbital
(100 mg/kg).
The animals were randomly divided into four groups
with 8 animals in each group, as follows:
I. Control group (n = 8); spinal cord tissue and
blood samples were obtained 72 h after a simple
laparotomy was performed.
II. I/R group (n = 8); 20 min of ischemia (abdominal
aortic occlusion)/72 h of reperfusion.
III. Experimental group (atorvastatin) (n = 8); 14 days
of pretreatment with atorvastatin/20 min of
ischemia/72 h of reperfusion, 2 days of atorvas-
tatin treatment during the reperfusion period.
IV. Experimental group (atorvastatin-withdrawal)
(n = 8); 14 days of pretreatment with atorvasta-
tin/20 min of ischemia/72 h of reperfusion.
Neurological examination
The neurological status of the animals was evaluated by
an independent observer who was unaware of the treatment
modality of the animal at 12, 24, 48 and 72 h using the
Tarlov scale. The animals were classified according to their
Tarlov score, as follows: 0 = no voluntary movement, spastic
paraplegia; 1 = perceptible movement of the hind limbs;
2 = good movement but unable to stand; 3 = able to stand
and walk; 4 = complete recovery (able to stand, walk and
run) (11).
Histopathological examination
The biopsy samples of the lumbosacral spinal cords were
fixed using a 10% formalin solution for 24 h. The samples
were embedded in paraffin and serial transverse sections
(4-mm thick) at the lumbosacral level were obtained. The
histopathology of the samples was evaluated by a pathol-
ogist who was blinded to the groups of the samples and
who rated the extent of neuronal destruction using
hematoxylin and eosin (H&E)-stained sections of the spinal
cords. According to the extent of vacuolization of the spinal
cord, the light microscopic findings were graded on a scale
from 0 to +3, corresponding to no change, mild, moderate
and severe changes, respectively. Cells that exhibited
eosinophilic cytoplasm, had lost Nissl granules or had lost
the nucleus were considered injured.
Biochemical analyses
Spinal cords and serum obtained from all rabbits in each
group were used for biochemical analyses. The spinal cord
tissues were washed twice using cold serum physiological
solutions and placed in labeled glass bottles. The bottles
were stored in a deep freezer (230 C˚) until processed
(maximum of 10 h). The spinal cords were cut into small
pieces using scissors followed by homogenization in four
volumes of ice-cold Tris–HCl buffer (50 mM, pH 7.4) using
a glass Teflon homogenizer (IKA ULTRA-TURRAX T-18
basic, USA) (for two minutes at 5000 rpm). The nitric oxide
(NO), malondialdehyde (MDA) and protein concentrations
of the homogenates were determined. The homogenates
were subsequently centrifuged to remove debris. The
supernatants were removed and the glutathione peroxidase
(GSH-Px) and xanthine oxidase (XO) activities and the
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protein concentrations of the supernatants were deter-
mined. The supernatants were extracted using an equivalent
volume of an ethanol/chloroform mixture. The super-
natants were subsequently centrifuged at 5000 6g for
30 min. The clarified upper layers were removed and
utilized to determine the superoxide dismutase (SOD)
activity and protein content. Certain values were deter-
mined at different stages of sample preparation because
certain biochemical markers may undergo oxidation during
the later stages of preparation. Furthermore, an extraction
procedure is required for the determination of SOD activity.
All of the preparation procedures were performed at +4 C˚.
Blood samples obtained by cardiac puncture were collected
into serum separation tubes. The blood samples were
centrifuged at 10006g for 10 min at 4 C˚ to separate the sera.
Determination of the MDA content
A method based on the reaction with thiobarbituric acid
(TBA) at 100 C˚ was used to determine the tissue and serum
MDA levels (12). The results are expressed as mmol/l for the
sera samples and as nmol/g protein for the spinal cord
tissues.
Determination of the NO content
Due to the difficulty in determining the NO concentration
in biological specimens, the tissue nitrite and nitrate levels
were determined as an index of NO production. The
method used to determine the nitrite and nitrate levels in
the spinal cord samples was based on the Griess reaction
(13). These values are expressed as mmol/g protein for the
spinal cord tissues and as mmol/l for the sera samples.
Determination of the SOD activity
The total SOD activity was determined using the method
described by Sun et al. (14). The results are expressed as U/
ml for the sera samples and as U/mg protein for the spinal
cord tissues.
Determination of the XO activity
The XO activity was spectrophotometrically determined
according to the method described by Prajda and Weber
(15). The results are expressed as U/ml for the sera samples
and as U/g protein for the spinal cord homogenates.
Determination of the GSH-Px activity
GSH-Px activity was determined according to the method
described by Paglia and Valentine (16). The results are
expressed as U/g protein for the spinal cord tissues.
Determination of the myeloperoxidase (MPO)
activity
4-Aminoantipyrine/phenol was used as the substrate for
the MPO-mediated oxidation by H2O2 to determine the
MPO activity (17). The results are expressed as mU/g
protein.
Determination of the protein concentration
The protein assays were performed as described by
Lowry et al. (18).
Power and sample size
The sample size of this study was calculated using the
G*Power (G*Power Ver. 3.00.10, Franz Faul, U¨niversita¨t
Kiel, Germany, http://www.psycho.uni-duesseldorf.de/
aap/projects/gpower/) statistical package based on the
Tarlov scores. The sample size required to achieve 80%
power, a= 0.05 Type I error, b= 0.20 Type II error and
f = 0.70 effect size was found to be 28, which included 7
New Zealand white rabbits in each group. To account for
potential losses to follow-up, one more rabbit was included
in each group and the study was conducted using a sample
size of 32.
Statistical analysis
The normality of the distribution of the biochemical
data for the sera and tissues were evaluated using the
Shapiro-Wilk test. Depending on whether these values
presented a normal distribution, the descriptive biochemical
values are presented as the mean values plus the mean
standard deviation or as the median (IQR, interquartile
range) values.
The spinal cord vacuolization values for the groups are
presented in cross-tables and the inter-group differences
were evaluated using the chi-squared test. The values for
the biochemical markers of each group were compared
depending on the normality of the distribution of these
values using the Bonferroni post-hoc one-way analysis of
variance (ANOVA) or the post-hoc Bonferroni-corrected
Mann-Whitney non-parametric Kruskal-Wallis analysis of
variance. The statistical analyses were conducted using
SPSS software (ver. 15.0, IBM, Chicago, IL, USA). A p-
value of less than or equal to 0.05 was considered
significant.
& RESULTS
Biochemical parameters
The MDA and NO levels and SOD activities in the sera
and spinal cord tissues and the MPO, XO and GSH-Px
activities in the spinal cord tissues are summarized in
Table 1.
Serum levels
The mean serum MDA levels of the experimental groups
were significantly different (F = 7.055, p= 0.001). The mean
serum MDA level of the I/R group (approximately
12.10 mol/l) was significantly higher than that of the control
group (p,0.001). The differences among the MDA values of
the remaining groups were not significant. The control
group exhibited the lowest mean serum MDA level and the
mean serum MDA level of the atorvastatin group was found
to be the most similar to that of the control group. The
highest mean serum MDA level was observed in the I/R
group.
The mean serum SOD activity was significantly different
in at least one of the evaluated groups. No significant
differences were observed between the SOD activities of the
atorvastatin and withdrawal groups (p= 1.000), whereas the
mean SOD activities of the remaining groups were
significantly different from each other (p,0.05) (Table 2).
The SOD activity of the withdrawal group was the most
similar to that of healthy rabbits (control). The lowest mean
serum SOD activity was observed in the I/R group.
The median serum NO level was significantly different in
at least one of the groups compared with the remaining
groups (x2 = 26.960; p,0.001). No significant differences
were observed between the serum NO levels of the
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atorvastatin and withdrawal groups (p= 1.000), whereas
those of the remaining groups significantly differed from
one another (p,0.05) (Table 2).
The median serum XO activities of the experimental
groups significantly differed (x2 = 17.356; p,0.001). The
median serum XO activities of the I/R and control groups
(p,0.001) and those of the atorvastatin (p= 0.001) and
withdrawal groups (p,0.001) were significantly different,
whereas those of the remaining groups were similar
(p.0.05) (Table 2).
Tissue levels
The mean tissue MDA levels of the experimental groups
were significantly different (F = 267.705; p,0.001) (Table 2).
The I/R group exhibited the highest mean tissue MDA
level, whereas that of the withdrawal group was most
similar to that of the I/R group.
The mean tissue SOD activity of at least one group was
significantly different from those of the remaining groups
(F = 45.455; p,0.001). No significant differences were
observed between the SOD activities of the I/R and
Table 1 - The levels and activities of various biochemical markers in the sera and spinal cord tissues of the experimental
groups.
Control (I) I/R (II) Atorvastatin (III) Withdrawal (IV) Statistical results*
Serum/Tissue Variable
Mean¡SD Median
(IQR)
Mean¡SD Median
(IQR)
Mean¡SD Median
(IQR)
Mean¡SD Median
(IQR) F/x2 p
SERUM MDA (mmol/l) 0.22¡0.02 0.32¡0.06 0.26¡0.04 0.27¡0.03 F= 7.055 0.001
SOD (U/ml) 15.73¡1.13 10.37¡0.71 13.58¡1.10 14.26¡0.95 F= 42.174 ,0.001
NO (mmol/l) 9.90 (0.76) 11.27 (0.89) 7.56 (0.67) 8.06 (1.12) x2 = 26.960 ,0.001
XO (U/ml) 0.08 (0.02) 0.20 (0.12) 0.03 (0.08) 0.06 (0.09) x2 = 17.356 ,0.001
TISSUE MDA (mmol/g) 17.28¡0.87 25.77¡0.40 19.67¡0.52 21.56¡0.59 F= 267.705 ,0.001
SOD (U/mg) 0.18¡0.02 0.53¡0.12 0.32¡0.03 0.48¡0.04 F= 45.455 ,0.001
NO (mmol/g) 0.23 (0.08) 1.19 (0.03) 0.92 (0.29) 1.06 (0.51) x2 = 19.472 ,0.001
XO (U/g) 0.24 (0.15) 0.85 (0.55) 0.29 (0.07) 0.25 (0.04) x2 = 20.367 ,0.001
MPO (mU/g) 2.53¡0.43 4.23¡0.35 2.88¡0.55 3.33¡0.51 F= 20.133 ,0.001
GSH-Px (U/g) 0.59¡0.07 0.52¡0.06 0.57¡0.03 0.62¡0.04 F= 4.899 0.007
*F: based on an ANOVA; x2: based on the Kruskal-Wallis test.
Table 2 - Results of pairwise comparisons of the biochemical markers in the sera and spinal cord tissues of the
experimental groups.
Control (I) I/R (II) Atorvastatin (III)
Group p (difference)** p (difference)** p (difference)**
SERUM MDA I/R (II) 0.001 (I,II)
Atorvastatin (III) 0.310 (nd) 0.098 (nd)
Withdrawal (IV) 0.274 (nd) 0.112 (nd) 1.000 (nd)
SERUM SOD I/R (II) ,0.001 (I.II)
Atorvastatin (III) 0.001 (I.III) ,0.001 (II,III)
Withdrawal (IV) 0.035 (I.IV) ,0.001 (II,IV) 1.000 (nd)
SERUM NO * I/R (II) ,0.001 (I,II)
Atorvastatin (III) ,0.001 (I.III) ,0.001 (II.III)
Withdrawal (IV) ,0.001 (I.IV) ,0.001 (II.IV) 0.083 (nd)
SERUM XO * I/R (II) ,0.001 (I,II)
Atorvastatin (III) 0.105 (nd) 0.001 (II.III)
Withdrawal (IV) 0.878 (nd) ,0.001 (II.IV) 0.574 (nd)
TISSUE MDA I/R (II) ,0.001 (I,II)
Atorvastatin (III) ,0.001 (I,III) ,0.001 (II.III)
Withdrawal (IV) ,0.001 (I,IV) ,0.001 (II.IV) ,0.001 (III,IV)
TISSUE SOD I/R (II) ,0.001 (I,II)
Atorvastatin (III) 0.002 (I,III) ,0.001 (II.III)
Withdrawal (IV) ,0.001 (I,IV) 0.991 (nd) ,0.001 (III,IV)
TISSUE NO * I/R (II) ,0.001 (I,II)
Atorvastatin (III) ,0.001 (I,III) 0.010 (nd)
Withdrawal (IV) ,0.001 (I,IV) 0.959 (nd) 0.721 (nd)
TISSUE XO * I/R (II) ,0.001 (I,II)
Atorvastatin (III) 0.038 (nd) ,0.001 (II.III)
Withdrawal (IV) 0.721 (nd) ,0.001 (II.IV) 0.105 (nd)
TISSUE MPO I/R (II) ,0.001 (I,II)
Atorvastatin (III) 0.848 (nd) ,0.001 (II.III)
Withdrawal (IV) 0.011 (I,IV) 0.003 (II.IV) 0.377 (nd)
TISSUE GSH-Px I/R (II) 0.062 (nd)
Atorvastatin (III) 1.000 (nd) 0.062 (nd)
Withdrawal (IV) 1.000 (nd) 0.006 (II,IV) 0.626 (nd)
*: obtained using the Bonferroni correction; ** nd: no difference.
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withdrawal groups (p= 0.991). However, the SOD activities
of the remaining groups were different from that of at least
one other group (p,0.01) (Table 2).
The median tissue NO level of at least one of the groups
was significantly different from that of the remaining
groups (x2 = 19.472; p,0.001). The average tissue NO level
of the control group was significantly different from those of
the remaining groups (p,0.001). The median tissue NO
levels of the remaining groups were similar (p.0.05)
(Table 2). The control group exhibited the lowest median
tissue NO level, whereas the I/R group exhibited the
highest median tissue NO level.
Significant differences were observed in the median tissue
XO activities of the experimental groups (x2 = 20.367;
p,0.001). The median tissue XO activities of the I/R and
control groups (p,0.001) and those of the atorvastatin
(p,0.001) and withdrawal groups (p,0.001) were signifi-
cantly different, whereas those of the remaining groups
were similar (p.0.05) (Table 2).
The mean tissue MPO activities of the experimental
groups were significantly different (F = 20.133; p,0.001).
The mean tissue MPO activities of the I/R and control
groups (p,0.001), those of the atorvastatin (p,0.001) and
withdrawal groups (p= 0.003) and those of the control and
withdrawal groups (p= 0.011) were significantly different,
whereas those for the remaining groups were similar
(p.0.05) (Table 2). The I/R group exhibited the lowest
mean tissue MPO activity, whereas the control group
exhibited the highest mean tissue MPO activity.
The mean tissue GSH-Px activities of the experimental
groups were significantly different (F = 4.899; p= 0.007). The
mean tissue GSH-Px activities of the I/R and withdrawal
groups (p= 0.006) were significantly different. No significant
differences were observed among the mean tissue GSH-Px
activities of the remaining groups (p.0.05) (Table 2). The
withdrawal group exhibited the lowest mean tissue GSH-Px
activity, whereas the I/R group exhibited the highest mean
tissue GSH-Px activity.
Neurological status of the treatment groups
All of the rabbits in the control group exhibited Tarlov
scores of 4 points at all of the evaluated time points. The
median Tarlov scores are summarized in Table 3. The
median Tarlov scores of the experimental group at 12, 24, 48
and 72 hours following spinal-cord injury were significantly
different (p,0.001). None of the rabbits in the experimental
group regained the ability to move in a manner observed for
the rabbits in the control group (p,0.001). The median
Tarlov scores of the control group were higher than those of
the remaining groups (p= 0.002).
The median Tarlov scores in the withdrawal group were
higher than those of the I/R group. No significant
differences were observed among the scores of the remain-
ing groups (p.0.05) (Figure 1). The median Tarlov scores at
24 h following spinal cord injury of the control and
withdrawal groups were similar (p= 0.010). The I/R and
atorvastatin groups exhibited lower median Tarlov scores
than that of the control group (p,0.001 and p,0.001,
respectively). The Tarlov scores of the I/R group were
lower than those of the atorvastatin (p= 0.007) and with-
drawal (p= 0.002) groups. No significant differences were
observed between the atorvastatin and withdrawal groups
(p= 0.505) (Figure 1).
The median Tarlov scores of the atorvastatin and with-
drawal groups were similar to those of the control group at
48 and 72 h post-ischemic injury (p= 0.010 and p= 0.038;
p= 0.038 and p= 0.038, respectively). The Tarlov scores of the
I/R group were lower than those of the atorvastatin and
withdrawal groups (p= 0.002 and p,0.001, respectively). No
significant differences were observed between the scores of
the atorvastatin and withdrawal groups at 48 or 72 h post-
ischemic injury (p= 0.798, p= 0.878) (Figure 1). No signifi-
cant differences were observed in the median Tarlov scores
of the animals in the I/R group at the evaluated time points
(x2 = 4.385; p= 0.223). No significant differences were
observed in the hind-limb motor-function scores of the
animals in the I/R group at the evaluated time points
(Figure 1).
The atorvastatin group exhibited a median Tarlov mobility
score at at least one time point that was different from that of
the remaining groups (x2 = 13.824; p= 0.003). Because the
scores at the evaluated time points were not significantly
different, pairwise comparisons using a Bonferroni correction
were performed to determine whether a time-dependent
median Tarlov score was significantly different in the
atorvastatin-treatment groups. The median Tarlov score of
the withdrawal group was significantly different at different
time points (x2 = 16.286; p= 0.001) (Figure 1). The hind-limb
motor functions of the withdrawal group significantly
improved between 12 and 72 h post-injury (Table 3). The
function scores at the remaining time points were not
significantly different (p.0.05) (Figure 1).
Table 3 - Median Tarlov mobility scores of the experimental groups at selected time points following ischemic injury.
Control (I) I/R (II) Atorvastatin (III) Withdrawal (IV) Statistical differences between the groups
Min – Max Min – Max Min – Max Min – Max
Time point (h) Median (IQR) Median (IQR) Median (IQR) Median (IQR) x2 p
12 h 4 – 4 0 – 1 0 – 3 1 – 3 24.266 ,0.001
4 (na) 0.5 (1.0) 2.5 (1.8) 2.0 (1.8)
24 h 4 – 4 0 – 2 1 – 3 1 – 4 22.886 ,0.001
4 (na) 1.0 (0.8) 3.0 (1.8) 3.0 (1.8)
48 h 4 – 4 0 – 2 2 – 4 2 – 4 22.968 ,0.001
4 (na) 1.0 (1.0) 3.0 (1.5) 3.0 (1.8)
72 h 4 – 4 0 – 2 1 – 4 2 – 4 21.309 ,0.001
4 (na) 1.0 (1.0) 3.0 (2.0) 3.0 (2.0)
Time-dependent
differences (x2; p)
na 4.385; 0.223 13.824; 0.003 16.286; 0.001
na: not available; h: hours.
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Histopathological evaluation
The vacuolization scores of the experimental groups are
summarized in Table 4. For the statistical analysis of these
scores, the vacuolization scores were combined into two
groups, as follows: group 1 included no and mild
vacuolization scores, whereas group 2 included moderate
and severe vacuolization scores. The distributions of the
vacuolization scores according to the experimental groups
are summarized in Table 5. No vacuolization or mild
vacuolization was observed in all of the rabbits in the
control group, whereas the highest level of vacuolization
was observed in the I/R group. All of the rabbits in the I/R
group exhibited moderate or severe vacuolization scores.
The vacuolization scores of the atorvastatin and withdrawal
groups were similar. The vacuolization scores were sig-
nificantly different between the experimental groups. The I/
R group exhibited higher vacuolization scores than those of
the remaining groups. The vacuolization scores were similar
in the control, atorvastatin and withdrawal groups (Figures 2
and 3).
& DISCUSSION
The findings of the present study can be examined
in terms of two primary endpoints. First, this study
demonstrated the neuroprotective effects of pre-ischemic
administration of atorvastatin in a spinal cord ischemia-
reperfusion model and, second, that the acute withdrawal of
atorvastatin therapy following spinal cord ischemia did not
increase the extent of neuronal damage compared with
continuous therapy during the reperfusion period.
Neuroprotective effects
Clinical studies have demonstrated that statin therapy
decreased the incidence of ischemic stroke, most likely
through effects on the precerebral atherosclerotic plaques
and antithrombotic mechanisms (6). Furthermore, statins
have been shown to decrease the infarct size in experimental
animal models of stroke. Statins upregulate the level of
endothelial nitric oxide synthase (eNOS) and inhibit the
production of inducible nitric oxide synthase (iNOS), effects
that are potentially neuroprotective (7,8). Our study
revealed a marked elevation in the NO level of the I/R
group and that atorvastatin treatment significantly attenu-
ated this increase. This increase in NO generation in the sera
of the I/R group supports a mechanism that involves the
generation of NO from free radicals produced under
oxidative stress. The preservation of eNOS activity in the
cerebral vasculature, particularly in the ischemic penumbra,
is highly important in preserving blood flow and limiting
the extent of neurological damage. Statins may also
attenuate the inflammatory cytokine responses that accom-
pany cerebral ischemia and they possess antioxidant
properties that likely ameliorate ischemic oxidative stress
in the brain (22). Simvastatin treatment has been shown to
reduce the extent of ischemic brain injury and perfusion
deficits in an embolic model of stroke (23).
Atorvastatin, which is a hypocholesterolemic agent,
exhibits anti-inflammatory, antithrombotic and antioxidant
activities (24,25). The potential anti-inflammatory activity
of atorvastatin may ameliorate neurological impairment
mechanisms that most likely result from the unpredictable
side effects of inflammatory cascades. Several studies have
Figure 1 - The median Tarlov scores of the experimental groups at various time points following ischemic injury.
Table 4 - The extent of vacuolization of the spinal cord
tissue for each group.
Vacuolization
Group None Mild Moderate Severe Total
Control n (%) 8 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 8
I/R n (%) 0 (0.0) 0 (0.0) 1 (12.5) 7 (87.5) 8
Atorvastatin n (%) 3 (37.5) 4 (50.0) 1 (12.5) 0 (0.0) 8
Withdrawal n (%) 2 (25.0) 5 (62.5) 1 (12.5) 0 (0.0) 8
Total n (%) 13 (40.6) 9 (28.1) 3 (9.4) 7 (21.9) 32
Table 5 - The combined results of the vacuolization of the
spinal cord samples for each group.
Vacuolization
Group None or mild Moderate or severe Total
Control n (%) 8 (100.0) 0 (0.0) 8
I/R n (%) 0 (0.0) 8 (100.0) 8
Atorvastatin n (%) 7 (87.5) 1 (12.5) 8
Withdrawal n (%) 7 (87.5) 1 (12.5) 8
Total n (%) 22 (68.8) 10 (31.3) 32
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indicated that atorvastatin exerts a neuroprotective effect on
spinal cord injury (26). Pannu et al. (27,28) reported that
atorvastatin treatment following traumatic injury of the
spinal cord attenuated the levels of inflammation, neuronal
apoptosis and demyelination and improved the functional
outcome. Dery et al. (29) found that following experimental
thoracic spinal cord contusion injury, atorvastatin was
effective in preventing early apoptosis at the injury site
within 2 h post-administration and in promoting locomotor
recovery. Eroglu et al. (30) demonstrated that the adminis-
tration of microspheres containing atorvastatin improved
the functional outcome of an experimental traumatic SCI
model, attenuating the expression of TNF-a, IL-1b and IL-6,
lowering the lipid peroxidation levels and preserving
cellular integrity. Nacar et al. (31) demonstrated that the
systemic administration of atorvastatin reduced the level of
expression of inflammatory cytokines, such as IL-1b and
IL-6, as well as the level of lipid peroxides following
experimental spinal cord injury in rats. These authors also
demonstrated the beneficial effect of atorvastatin treatment
in terms of the Tarlov scores. The results of our current
investigation are similar to the outcomes observed by Nacar
et al.
In this study, administration of atorvastatin prior to
ischemia-reperfusion injury protected the spinal cord, as
indicated by the improved neurological function based on a
higher Tarlov score. The administration of atorvastatin
(groups III and IV) resulted in a significant reduction in
motor dysfunction. The improved neurological functional
outcome was supported by the light microscopic observa-
tion of more intact cellular structures. The motor neurons in
the animals of the I/R group were completely destroyed.
The administration of atorvastatin (groups III and IV)
attenuated the ischemia-induced histopathological injury.
Medulla spinalis I/R injury is defined by a complex cascade
of events, including the increased liberation of reactive
oxygen species (ROS) from a variety of cell types. The role of
ROS in I/R spinal cord injury has been examined through
detection of the by-products of oxidation of target molecules
(lipid peroxidation and protein oxidation) and determina-
tion of the consumption of tissue antioxidants, such as GSH.
Numerous studies have shown a positive correlation
between increased levels of antioxidant enzymes in the
spinal cord and/or decreased levels of antioxidant defense
(19,20,21).
Our study indicated that atorvastatin significantly inhib-
ited the depletion of SOD, XO and MPO activities in spinal
cord tissue. This preventive effect may be due to the free
radical scavenging and antioxidant activities of atorvastatin.
Moreover, atorvastatin significantly reduced the increase in
the MDA concentration in rabbit spinal cord tissue. In this
study, lipid peroxidation was monitored by measuring the
level of MDA, which is produced from free radical damage
of the membrane components of cells. We observed a
significant increase in the MDA concentration in the spinal
cord tissue of the rabbits in the I/R group. Atorvastatin
significantly attenuated this increase in the MDA concentra-
tion. This observation is most likely due to the ROS
Figure 2 - Spinal cord samples of the I/R group with paraplegia exhibited complete destruction of the motor neurons, with intensely
eosinophilic cytoplasm, the loss of Nissl granules and the pronounced vacuolization of the substantia alba (SA) and the substantia
grisea (SG). A) Hematoxylin and eosin (H&E)-stained spinal cord tissues at 2006magnification and B) H&E-stained spinal cord tissues at
4006magnification.
Figure 3 - A) Histopathological features of the spinal cords of rabbits with healthy cells in the substantia grisea (SG) and a mild level of
vacuolization in the substantia alba (SA) (H&E, 2006). B) Representative micrograph showing a moderate level of vacuolization (arrow)
in the cells of the substantia grisea (H&E, 4006). C) Representative micrograph showing vacuolization, neurons containing pyknotic
nuclei (thick arrow) and sparse Nissl-stained substances (thin arrow) in the cytoplasm of the large neurons in the substantia grisea (H&E,
4006).
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scavenging capacity of atorvastatin. The atorvastatin-
mediated protection of the spinal cord from I/R injury
may also be due to the reduction of the level of lipid
peroxidation in the neurons of the spinal cord. MPO is an
enzyme that is expressed in leukocytes. The increased levels
of MPO in the spinal cord tissue following I/R suggest
leukocyte infiltration into the spinal cord. According to our
findings, the MPO levels were elevated in the tissues of the
I/R group and atorvastatin treatment prevented this
elevation, protecting the spinal cord. In summary, we
observed that atorvastatin treatment improved the extent
of locomotor recovery following ischemic spinal cord injury
in rabbits. This result was confirmed by the determined
levels of lipid peroxidation and antioxidant enzymatic
activities and the histopathological findings. These findings
revealed the antioxidant activity and beneficial neuropro-
tective effect of atorvastatin on rabbit SCI.
Effects of the withdrawal therapy
No differences were observed in the neurological and
histopathological findings of the acute withdrawal group
and the group in which atorvastatin administration was
continued during the reperfusion period following ische-
mia. Regarding the neurological functional outcome, no
significant differences were observed in the motor function
scores of groups III and IV at the evaluated time points.
Under ischemic conditions, no significant morphological
differences were observed between groups III and IV, either
grossly or microscopically. However, significant differences
were observed between the I/R group and the groups that
were administered atorvastatin (groups III and IV).
Regarding the oxidative stress parameters, no significant
differences were found between the values of the serum
biochemical markers of groups III and IV. However,
significant differences in two markers (MDA and SOD) of
tissue oxidative stress were observed in these 2 groups.
Additionally, the GSH-Px activity in the spinal cord tissue of
the withdrawal (IV) group was higher than that of the
control (II) group. However, the effects of these differences
were not reflected in the results of the neurological and
histopathological examinations.
Acute termination of statin treatment may suppress the
production of endothelial NO and impair vascular function
(32). In our study, a marked elevation in the tissue NO level
was observed in groups II, III and IV; however, no
difference was observed in the NO levels of the withdrawal
group and the group in which treatment with atorvastatin
was continued during the reperfusion period. Gertz et al.
(33) have reported that the withdrawal of atorvastatin
treatment leads to the rapid abrogation of statin-mediated
stroke-protective effects. However, we did not observe
additional deterioration of neurological function due to
the withdrawal of statin therapy compared with the group
in which statin administration was continued during the
reperfusion period. Furthermore, no significant differences
were found between groups III and IV in the biochemical
and histopathological evaluations.
This study demonstrates a considerable neuroprotective
effect of atorvastatin on the neurological, biochemical and
histopathological status in ischemia-induced spinal cord
injury in rabbits. However, the acute withdrawal of
atorvastatin therapy following the induction of spinal cord
ischemia did not increase the extent of neuronal damage in
this rabbit model.
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